Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Status unconfirmed · Phase 1
Conditions studied: HIV Infections
In brief
This study is to test a therapeutic HIV-1 vaccine (HIVAX™) in HIV-1 infected subjects. The safety and immune responses will be studied in vaccine recipients. The anti-viral effect of HIVAX vaccine will be monitored during a 12-week treatment interruption phase.
Key facts
- Study ID
- NCT01428596
- Run by
- GeneCure Biotechnologies
- People needed
- 30
- Starts
- 2010-09-01
- Expected to finish
- 2020-12-01
- Last updated by the study team
- 2020-06-09
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Miami School of Medicine, AIDS Clinical Research unit — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.